Last reviewed · How we verify

NCT05899387: SerMa

Seroma of the Mammary Gland

Recruiting now NA Last updated 28 February 2025
What this trial tests

NA trial testing Swap collection in Seroma in 2,000 participants. Currently enrolling.

Timeline
1 April 2024
Primary endpoint
1 July 2027
1 July 2027

Quick facts

Lead sponsorUniversity Hospital Augsburg
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment2,000
Start date1 April 2024
Primary completion1 July 2027
Estimated completion1 July 2027
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Augsburg

Who can join

18 and older, female only, with Seroma or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is designed as international, prospective, minimal interventional study in cooperation with EUBREAST e.V. (European Breast Cancer Research Association of Surgical Trialists). Furthermore, it is planned to initiate a registry for postoperative breast seromas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Seroma

Currently open trials in the same condition.

Other University Hospital Augsburg trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05899387.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing